83 results
To validate and extend findings from the TACT sytudy group as well as our own preliminary data in a randomized, placebo controlled study in patients with and without diabetes.
The objective of this study is to determine the Safety and Efficacy of ADRCs delivered via the intracoronary route in the treatment of patients with ST-elevation acute myocardial infarction (STEMI).Investigation of stem and regenerative cell therapy…
1. The primary objectives of this phase I/II clinical trial is to demonstrate feasibility and evaluate the safety and toxicity of ACT plus vaccination according to CTCAE 4.0 criteria.2. Secondary objectives include the evaluation of the clinical…
conform nederlandse tekst
This study is designed to compare the treatment of 2 groups: autologous tenocytes injection in combination with exercises versus saline injection in combination with exercises.
The objective of this study is to demonstrate superior efficacy and evaluate the safety of MACI Implant compared with arthroscopic microfracture in the treatment of patients (aged 18 to 55 years old) with symptomatic articular cartilage defects of…
This is an exploratory study, consisting of two parts. In part I a dose escalation is performed and the primary objective is the safety of different doses of TLR-DC. In part II TLR-DC vaccination will be compared with cytokine-matured DC vaccination…
To determine the efficacy and the safety of PREOB, a proprietary population of autologous bone-forming cells, in the treatment of non-infected hypotrophic non-union fractures of long bones.
The primary goal is to show the capability of monocyte-derived DC after RNA electroporation for melanoma antigens to induce an immune response.The secondary objective is to show clinical response.
In this phase I/II clinical study will assess the safety, effectiveness and homing of asCTMP, namely autologous mesoangioblasts, that will be injected 3x intra-arterially in right lower leg via catheter in 5 indivuals that carry the m.3243A>G…
The overall study objective is to evaluate the safety and efficacy of NiCord®: single ex-vivo expanded cord blood unit transplantation in patients with hematological malignancies following myeloablative therapy.
To evaluate the safety and toxicity of ACT and low-dose IFN-alpha plus nivolumab according to CTCAE 4.0 criteria. Toxicity grade 3 or less and SAE related to treatment but that do not result in treatment termination are considered acceptable for…
A pilot feasibility study (n=5) will be performed to evaluate the feasibility (logistics, timing) and safety of administering autologous tumor infiltrating lymphocytes (TIL) generated at the NKI-AVL infused in conjunction with systemic high-dose…
The primary goal is to show the capability of monocyte-derived DC after RNA electroporation for multiple antigens to induce an immune response. The secondary objective is to show clinical response.
ObjectiveEvaluation of the application of cultured autologous keratinocytes in combination with a meshed split skin autograft to improve burn wound healing
The primary objective of the study is to evaluate the efficacy of intralesional administration of eASCs (CX-401) when added to standard surgical care and drainage for the treatment of complex perianal fistulas in patients with Crohn*s disease (CD).
> Primary Objective:This is a pilot study, aiming at the clinical evaluation with respect to safety and feasibility of a one-step surgical procedure for maxillary sinus floor augmentation for the placement of dental implants, using a ceramic…
The primary objective of the study is:- to establish the safety and feasibility of infusion of escalating doses of autologous ASC in end-stage renal disease patients. Secondary objectives are:- to determine the effect of ASC infusion on kidney…
The primary objective is the safety and feasibility of CEA/frameshift derived neopeptide loaded DC in patient with MSI-positive colorectal cancer and persons who are known to be carrier of a germline MMR-gene mutation with no signs of disease yet.…
The study will evaluate the injection of AMDC for Urinary Sphincter Repair (USR) compared to a placebo dose, with the hypothesis that one or two treatments of AMDC is statistically superior to placebo at 12 months following the initial treatment.